IDYA vs SLS
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
IDYA · IDEAYA Biosciences$25.56 ▼ 2.33%
SLS · Sellas Life Sciences$13.66 ▼ 8.08%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- IDYA -26.3%
- SLS +781.3%
Head to head
| Metric | IDYA | SLS |
|---|---|---|
| Price | $25.56 | $13.66 |
| Change today | ▼ 2.33% | ▼ 8.08% |
| Market cap | $2.47B | $2.78B |
| Return, 3 months | -36.2% | -4.7% |
| Return, year to date | -26.1% | +262.3% |
| Return, 1 year | -24.8% | +792.8% |
| P/E (TTM) | – | – |
| P/B | 2.3 | 21.1 |
| P/E percentile vs own 5y | 83rd | 8th |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | -95.1% | – |
| Net profit growth (YoY) | -205.5% | -48.6% |
| Gross margin | – | – |
| Operating margin | -1,267.3% | – |
| Net margin | -1,149.6% | – |
| Return on equity | -38.5% | -40.3% |
| Analyst target vs. price | +107.0% | +119.6% |
| Analyst buy share | 100% | 100% |
| RSI (14) | 25 | 56 |
| 30-day volatility | 52.8% | 304.0% |
| Max drawdown, 1 year | -39.8% | -51.7% |
| Trend read | Strong downtrend | Strong uptrend |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- SLS is the largest of the group by market value.
- SLS has returned the most over the past year.
- IDYA has been the calmest stock over the last 30 days.